Entecavir

Generic Name: Entecavir

Brand Names: Baraclude, Entecavir Viatris (previously Entecavir Mylan), Entecavir Accord

Drug Type: Small Molecule

Chemical Formula: C_₁₂H_₁₅N_₅O_₃

CAS Number: 142217-69-4

Unique Ingredient Identifier: NNU2O4609D

Background: Entecavir is an oral antiviral drug used in the treatment of hepatitis B infection. It is marketed under the trade name Baraclude (BMS).

Entecavir is a guanine analogue that inhibits all three steps in the viral replication process, and the manufacturer claims that it is more efficacious than previous agents used to treat hepatitis B (lamivudine and adefovir). It was approved by the U.S. Food and Drug Administration (FDA) in March 2005.

Indication: For the treatment of chronic hepatitis B virus infection in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.

Associated Conditions: Chronic Hepatitis B Infection

Clinical Trials

HIV Drugs Show Promising Potential to Reduce Alzheimer's Risk by Up to 13% Annually

14 days ago

• UVA Health researchers discovered that HIV medications called NRTIs significantly reduce Alzheimer's risk, with annual decreases of 6-13% observed across two major health insurance databases. • The protective effect appears specific to NRTIs, which block inflammasomes linked to Alzheimer's development, and could potentially prevent approximately 1 million new cases worldwide each year. • Researchers are now calling for clinical trials of both existing NRTIs and a newly developed inflammasome-blocking drug called K9, which they describe as a safer and more effective alternative.

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy